Skip to main content
PLOS One logoLink to PLOS One
. 2021 Jul 26;16(7):e0255173. doi: 10.1371/journal.pone.0255173

Seroprevalence and associated factors of HIV and Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study

Lirane Elize Defante Ferreto 1,2,#, Stephanny Guedes 3,#, Fernando Braz Pauli 2,#, Samyra Soligo Rovani 2,#, Franciele Aní Caovilla Follador 2,#, Ana Paula Vieira 2,#, Renata Himovski Torres 4,#, Harnoldo Colares Coelho 5,#, Guilherme Welter Wendt 1,*,#
Editor: Yury E Khudyakov6
PMCID: PMC8312944  PMID: 34310633

Abstract

The prevalence of hepatitis C virus (HCV) and the acquired immunodeficiency virus (HIV) is much higher in prisons than in community settings. Some explanatory factors for this burden include putative aspects of the prison environment, such as unprotected sexual relations and sexual violence, use of injectable drugs and syringe sharing. Nonetheless, efforts in better understanding the dynamics of both HCV and HIV are scarce in developing countries such as Brazil, which poses a risk not only to the inmates but to the community as well. In this investigation, we sought to determine the seroprevalence and sociodemographic and behavioral risk factors associated with HIV and anti-HCV antibodies among men detained at high-security institutions. This is an epidemiological, proportionally stratified observational study including 1,132 inmates aged 18 to 79 years-old (Mage = 32.58±10.18) from eleven high-security prisons located in the State of Paraná, Brazil. We found that HIV and anti-HCV prevalence were 1.6% (95% CI: 1.0–2.5) and 2.7% (95% CI: 1.0–2.5), respectively. Risk factors associated with HIV included not receiving intimate visits (OR = 8.80, 95% CI: 1.15–66.88), already having another sexually transmitted infection (OR = 3.89, 95% CI: 1.47–10.29), and reporting attendance in HIV preventive campaigns (OR = 4.24, 95% CI: 1.58–11.36). Moreover, anti-HCV seroprevalence was associated with higher age (OR = 4.03, 95% CI: 1.61–10.07), criminal recidivism (OR = 2.58, 95% CI 1.02–6.52), and the use of injectable drugs (OR = 7.32, 95% CI 3.36–15.92). Although prisons might increase the risk for acquiring and transmitting HIV and HCV, the adoption of permanent epidemiological surveillance programs could help reducing the circulation of viruses, involving strategies focusing on screening, treating, and preventing infections to assure proper prisoner health. Moreover, these policies need to take place inside and outside the prison environment to offer continued assistance to former prisoners once they leave the institution.

Introduction

Viruses causing both hepatitis C (HCV) and the acquired immunodeficiency virus (HIV) are of critical concern in developed and developing countries, including Brazil [1, 2]. Between 1999 to 2018, 359,673 HCV cases were reported in Brazil; during this same period, detection rates in Southern regions were higher compared to other regions, with 26.8 cases per 100,000 inhabitants [3]. In relation to HIV, cumulative cases from 1980 to 2020 indicate a total of 1,011,617 diagnosis [4].

Despite the high rates of HCV and HIV infection in the community, there are populations with even greater vulnerability, such as prisoners [5, 6]. Indeed, prisoners are 48 to 69 times more likely to be infected with HCV and 7 to 12 times more likely to be infected with HIV when compared to the general population [7]. Moreover, there are around 10 million incarcerated individuals across de world, with 3.8% and 15.1% infected with HIV and HCV, respectively [8]. However, substantial regional variation in these estimates exists. For instance, HCV prevalence in Eastern Europe and central Asia region is around 20.2%, while numbers decline in Western Europe (15.5%), and in North (15.3%) and Latin America (4.7%); additionally, HIV prevalence among prisoners is also higher in East and South Africa (15%) in comparison to the 5% reported in Central Asia, Eastern and Western Europe [8].

Some scholars argue that HIV and HCV prevalence are higher in prisoners due to widespread criminalization of addiction, leading to conviction and detention of drug users [8, 9]. Despite the specific risks underpinning infection among drug users, the prison environment itself accentuates the odds of acquiring infectious diseases. This occurs as risky behaviors–including injecting drug use (IDU), needle sharing, tattoos and unprotected sexual practices–tend to increase when individuals are incarcerated [1]. HIV and HCV infection also varies between subgroups of inmates, especially among men who have sex with men (MSM), sex workers (SWs), IDU, and transgender women (TGW) [911]. The consequences of incarceration and infection by HIV and HCV are vast and well-documented, having a cascading effect on multiple levels. For individuals, synergistic deficits increase the susceptibility for disease progression, multimorbidity, psychiatric suffering, and death [12, 13]. For prison health and management, the duty of properly caring for serious physical and mental needs, coupled with efficient integration with external health services, are certainly challenging [14]. Lastly, societal implications must be considered, including public health concerns as former prisoners might not seek specialized and early care due to untreated conditions, notwithstanding the higher chances of recidivism and difficulties in resocialization commonly seen [13, 15].

HCV is about ten times more transmittable by percutaneous exposure and has an even greater association with IDU than HIV [16]. Moreover, IDU are six times more likely of contracting HIV while in prison [17, 18]. Thus, the absence of interventions and access to treatment for both sexually transmitted infections (STIs) and addition might maintain high levels of syringe sharing, which then raises transmission rates and risks for reincarceration [17].

Despite the syndemic of STIs, data on HIV and viral hepatitis in prison populations are still insufficient and or poorly reported, especially in low-income nations [19, 20]. To overcome the limitations regarding prisoners’ health and the limited resources for prevention and treatment [9, 18, 21], this investigation sought to explore the seroprevalence and associated risk factors for HIV and HCV infection in male inmates. We anticipated that IDU, previous STIs, and unprotected sexual behaviors would be associated with both HIV and HCV [1].

Methods

Study design and setting

This is a state-wide epidemiological and observational study conducted in 11 maximum security prisons for males, chosen out of a total of 23 institutions with around 19,000 total inmates from May 2015 to December 2016. The institutions are spread across the Paraná state (Brazil), covering small (Francisco Beltrão; FBE), medium (Londrina; LON), and large cities (Curitiba metropolitan region; CWB), thus representative of the large population of prisoners. In FBE, data were collected at the State Penitentiary; in LON, data was collected at the LON State Penitentiary I, LON State Penitentiary II, and in the Center for Social Reintegration; in the CWB metropolitan area, data were gathered from Piraquara State Penitentiary I and II, the Central State Penitentiary, Curitiba Forensic Unit, and from the Detention Centers in São José dos Pinhais, Piraquara, and Curitiba. The criteria for selecting those cities were based on the fact of having maximum security prisons that provide daily supervision within the prison limits, and for representing different demographic scenarios. Proportional stratified sampling was performed using each prison as a randomization unit.

Participants

The population included 8,142 inmates, and the sample size (n) involved 1,132 inmates (Mage = 32.58±10.18; range: 18 to 79 years). Participants were serving sentences of an average of 12.64 years (SD = 13.55), ranging from less than one year to 99 years. Sample size was calculated based on an expected anti-HIV seroprevalence of 50%±1% [22, 23] with a power of 80% and α = .03, which yielded the necessity of 954 inmates.

Procedures

Participation in the study was voluntary and no compensation was provided. Individuals were informed about their option to end their participation in the study at any time without consequences, thus offering to everyone the opportunity to be screened for HIV and anti-HCV. Ethical clearance was obtained from the Western Paraná State Research Ethics Committee (n. 33349314.9.0000.0107). On the day of data collection, prisoners were ranked numerically in ascending order according to lists provided by each prison unit. A list of random numbers was generated using Microsoft Excel® and participants were randomly chosen. To be included, participants had to be in state’s custody, be ≥18 years and able to consent for themselves in taking part in the research. Written informed consents were obtained from all individuals. Those who agreed to share the results from the serological testing with the institutions medical personnel had their records updated and, if necessary, guidance was offered to health staff.

An interview was conducted to gather information of potential risk factors for HIV and HCV infection (i.e., sexual behavior, drug usage, among others [Table 1]) in addition to sociodemographic variables (i.e., age, education, among others [Table 1]). Subsequently, participants were submitted to blood collection via venous puncture. Blood analyses were performed at Biocenter Lab (Foz do Iguaçu, Brazil) involving fourth-generation ARCHITECT HIV Ag/Ab combo assay® (Abbott Diagnostics, Wiesbaden, Germany). HIV reagent results were confirmed with GeeniusTM HIV 1/2 confirmatory assay and Western Blot (Biorad®, Santo Amaro, Brazil). Inconclusive results were tested twice and received reagent, non-reactive, or inconclusive diagnosis. ARCHITECT Anti-HCV high throughput chemiluminescent microparticle immunoassay was used to investigate HCV seroprevalence (Architect® Anti-HCV Assay, Germany).

Table 1. Demographic information from 1,132 inmates from 11 high-security prisons in the State of Paraná, Brazil (n = 1,132).

n %
Municipality
    Francisco Beltrão 119 10.51
    Londrina 276 24.38
    Curitiba 737 65.10
Age (years)
    Between 18 and 30 582 51.41
    More than 30 550 48.58
Ethnicity
    White 447 39.48
    Brown 477 42.13
    Asian 23 2.03
    Black 156 13.78
    Indigenous 29 2.56
Marital status
    Single 604 53.35
    With someone 528 46.64
Has children
    Yes 750 66.25
    No 382 33.74
Education
    Incomplete primary education 1082 95.59
    Complete primary education 50 4.41
Recidivism
    None or one 725 64.04
    Two or more 407 35.95
Sentence time
    Up to 10 years 1090 96.30
    More than 10 years 42 3.7
Sexually transmitted infection
    Yes 172 15.20
    No 960 84.80
Having tattoo
    Yes 808 71.37
    No 324 28.62
Having piercings
    Yes 420 37.10
    No 712 62.90
Sharing objects
    Yes 839 74.11
    No 293 25.88
Knowledge on HIV
    Yes 917 81.00
    No 215 19.00
Knowledge on HCV
    Yes 444 39.22
    No 688 60.77
Attending preventive campaigns
    Yes 90 7.95
    No 1042 92.05
Blood transfusion
    Yes 156 13.8
    No 976 86.20
Having sexual relationships with drug users
    Yes 670 59.20
    No/Do not know 462 40.80
Being a drug user
    Yes 850 75.00
    No 282 25.00
Alcohol use
    Yes 1062 93.81
    No 70 6.18
Being an inject drug user
    Yes 97 8.56
    No 1035 91.43
Self-reported sexual orientation
    Heterosexual 1034 91.34
    Other 98 8.65
Having homosexual sex
    Yes 66 5.83
    No 1066 94.17
Receiving intimate visits
    Yes 372 32.86
    No 760 67.13
Receiving/having condoms in prison
    Yes 564 49.82
    No/Do not know 568 50.18

Data analysis

Data were entered and analyzed using the Statistical Package for the Social Science (SPSS), version 24.0 (SPSS Inc., Chicago, IL, USA). Descriptive and inferential statistics were used to determine the prevalence of HIV and anti-HCV as well as to describe the study’s sample. Multivariate modelling was used to obtain raw and adjusted odds ratios (OR) of factors associated with positive HIV and anti-HVC results. Following past research on the matter [6, 20], adjusted OR with 95% confidence intervals (CI) were calculated in the multivariate logistic analyses to reduce bias regarding unequal sizes in the comparison groups.

Results

Table 1 provides a general overview of the demographic information about the studied samples. Notably, participants had low educational levels, with elevated proportion of drug users. The number of inmates reporting having sexual intercourse with drug users or not knowing whether their sexual partners were drug users was also noteworthy.

Table 2 presents the overall seroprevalence of anti-HVC antibodies and HIV in the total sample and in relation to a series of demographic and behavioral variables. Remarkably, MSM, aged over 30, with higher recidivism, without piercings and reporting IDU showed statistically higher seroprevalence of anti-HCV. On the other hand, prevalence of HIV was higher in individuals who already had STIs and in those that reported having participated in preventive campaigns against STIs, and in men who did not receive intimate visits.

Table 2. Prevalence of anti-HCV and HIV in 1,132 from 11 high-security prisons in the State of Paraná, Brazil (n = 1,132).

anti-HCV p HIV p
Frequency of positive results Prevalence (95% CI) Frequency of positive results Prevalence (95% CI)
Overall 30 2.7 (1.9–3.8) 18 1.6 (1.0–2.5)
Municipality .12 .26
    Francisco Beltrão 1 0.8 (0.1–4.0) 0 nc
     Londrina 6 2.2 (0.9–4.4) 5 1.8 (0.6–4.3)
    Curitiba 23 3.1 (2.2–5.8) 13 1.8 (1.0–3.0)
Age (years) .001 .91
    Between 18 and 30 6 1.0 (0.1–2.0) 10 1.7 (0.8–3.2)
    More than 30 24 4.4 (2.9–6.4) 8 1.5 (0.6–2.9)
Education .86 .40
    Incomplete primary education 12 2.7 (1.6–4.5) 7 1.6 (0.6–3.2)
    Complete primary education 18 2.6 (1.5–4.2) 11 1.6 (0.8–2.8)
Recidivism .01 .09
    None or one 6 1.2 (0.5–2.5) 4 0.8 (0.2–2.1)
    Two or more 24 3.8 (2.6–5.7) 14 2.2 (1.3–3.8)
Sentence time .35 .31
    Up to 10 years 13 2.1 (1.2–3.7) 7 1.2 (0.5–2.4)
    More than 10 years 17 3.2 (2.0–5.1) 11 2.1 (1.1–3.7)
Sexually transmitted infection .18 .003
    Yes 12 3.8 (2.1–6.7) 11 3.5 (1.9–6.3)
    No 17 2.2 (1.4–3.5) 7 0.9 (0.3–1.8)
Having tattoo .86 .48
    Yes 9 2.8 (1.4–5.3) 7 2.2 (0.9–4.5)
    No 21 2.6 (1.7–4.0) 11 1.4 (0.7–2.5)
Having piercings .03 .37
    Yes 5 1.2 (0.4–2.8) 9 2.1 (1.1–4.1)
    No 25 3.5 (2.4–5.1) 9 1.3 (0.6–2.4)
Sharing objects .46 .24
    Yes 10 3.4 (1.8–6.3) 16 1.9 (1.2–3.1)
    No 20 2.4 (1.5–3.7) 2 0.7 (0.1–2.6)
Knowledge on HIV .92 .58
    Yes 25 2.7 (1.8–4.0) 16 1.7 (1.1–2.8)
    No 5 2.3 (0.8–5.5) 2 0.9 (0.1–3.6)
Knowledge on HCV .30 .78
    Yes 15 3.4 (2.0–5.5) 6 1.4 (0.5–3.0)
    No 15 2.2 (1.3–3.6) 12 1.7 (0.9–3.1)
Attending preventive campaigns .95 .001
    Yes 3 3.1 (0.9–8.0) 6 5.5 (2.5–11.1)
    No 26 2.6 (1.8–3.8) 11 1.1 (0.6–2.0)
Blood transfusion .22 .99
    Yes 7 4.4 (2.0–9.0) 2 1.3 (0.1–4.8)
    No 23 2.4 (1.6–3.5) 16 1.6 (0.9–2.7)
Having sexual relationships with drug users .92 .37
    Yes 18 2.7 (1.7–4.2) 13 1.9 (1.1–3.3)
    No/Do not know 10 2.6 (1.4–4.5) 3 1.1 (0.3–2.6)
Being a drug user .09 .27
    Yes 27 3.2 (2.2–4.6) 16 1.9 (1.1–3.1)
    No 3 1.1 (0.2–3.2) 2 0.7 (0.1–2.7)
Alcohol use .20 .91
    Yes 26 2.4 (1.7–3.6) 17 1.6 (1.0–2.6)
    No 4 5.7 (1.8–14.2) 1 1.4 (0.1–12.4)
Being an inject drug user .001 .41
    Yes 13 13.4 (7.9–21.8) 3 3.1 (0.7–9.1)
    No 17 1.6 (1.0–2.6) 15 1.4 (0.8–2.4)
Self-reported sexual orientation .95 .42
    Heterosexual 28 2.7 (1.9–3.9) 15 1.5 (0.9–2.4)
    Other 2 2.0 (0.1–7.6) 3 3.1 (0.7–9.0)
Having homosexual sex .03 .65
    Yes 5 7.6 (2.9–6.9) 2 3.0 (0.2–1.0)
    No 25 2.3 (1.6–3.5) 16 1.5 (0.9–2.4)
Receiving intimate visits .60 .02
    Yes 8 2.2 (1.0–4.3) 1 0.3 (0.1–1.7)
    No 22 2.9 (1.9–4.4) 17 2.2 (1.4–3.6)
Receiving/having condoms in prison .83 .80
    Yes 16 2.8 (1.7–4.6) 10 1.8 (0.9–3.3)
    No/Do not know 9 2.5 (1.4–4.1) 5 1.4 (0.7–2.8)

CI: Confidence Intervals; NC: non computed; In bold, significant differences between rows.

Tables 3 and 4 present factors associated with anti-HCV serological status and HIV infection among 1,132 high-security inmates, respectively. Age, recidivism, and IDU were significantly associated with the presence of anti-HCV antibodies (Table 3), while not receiving intimate visits, attending STIs preventive campaigns and possessing other STIs were linked with higher odds of having HIV (Table 4). Independently from the other variables, individuals who reported injecting drugs had seven times more chances for presenting with anti-HCV antibodies in comparison to those that did not exhibit this behavior.

Table 3. Factors associated with anti-HCV antibodies seroprevalence in 1,132 high-security inmates.

ORraw (95% CI) p ORadjusted (95% CI) p
Age
    Between 18–30 1
    > 30 4.38 (1.77–10.80) .001 4.03 (1.61–10.07) .003
Recidivism
    Yes 3.33 (1.35–8.22) .009 2.58 (1.02–6.52) .04
    No 1
Has piercing
    Yes 1 --- ---
    No 3.02 (1.15–7.95) .02
Injecting drug user
    Yes 9.27 (4.35–19.73) < .001 7.32 (3.36–15.92) < .001
    No 1
Homosexual relations
    Yes 3.41 (1.26–9.22) .016 --- ---
    No 1

CI: Confidence Intervals. OR: Odds ratios; In bold, significant differences between rows.

Table 4. Factors associated with HIV infection in 1,132 high-security inmates.

ORraw (95% CI) p ORadjusted (95% CI) p
History of sexually transmitted infection
    Yes 4.23 (1.62–11.00) .003 3.89 (1.47–10.29) .006
    No/Do not know 1 1
Attended preventive campaigns for HIV/HCV
    Yes 5.22 (1.99–13.73) .001 4.24 (1.58–11.36) .004
    No 1 1
Receives intimate visit
    Yes 1 1
    No 8.49 (1.12–64.03) .038 8.80 (1.15–66.88) .036

CI: Confidence Intervals. OR: Odds ratios; In bold, significant differences between rows.

Multivariate analyses for HIV outcome maintained the raw OR in the adjusted, final model. In summary, when compared to individuals who received intimate visits, those who reported not receiving them had nine times more chances of HIV infection. Those who reported having STIs and those who participated in preventive campaigns against them were also more likely to have a positive HIV status.

Discussion

In this investigation, the goal was to explore the sociodemographic and behavioral risk factors associated with HIV and anti-HCV seroprevalence in men detained at high-security institutions, expanding on past research conducted in other Brazilian states that used mixed samples of inmates [20, 24]. Data describes a profile of vulnerability among participants, in which low education and high drug usage was reported. These factors could partly explain the burden of infectious diseases and other physical and mental suffering among Brazilian inmates [19] and are quite different from studies conducted in other regions of the country. For instance, in the current research, the percentage of IDU was way higher than the one reported by Sgarbi and colleagues (0%) and by Puga and collaborators (5.56%) in the Brazilian state of Mato Grosso, while lower education was much more frequent in our investigation in comparison to these investigations [20, 24].

Incarceration is associated with higher occurrence of infectious diseases, with expressive variation between countries. However, there is a consensus that, when compared to the general population, the prevalence of both HIV and HCV is extremely superior in these contexts [18, 25, 26]. Despite all the importance around the topic, there seems to exist a gap in studying and reporting data relating STIs in prisons and its potential impact in the community [8, 18]. The seroprevalence found in our study of anti-HCV antibodies (2.7%) and HIV (1.6%) was lower in comparison to global estimates. Indeed, a systematic review showed that around 15.1% and 3.8% of prisoners present HCV and HIV infection, respectively [8].

According to the literature, the susceptibility for HIV infection is amplified in individuals with history of STIs, being aggravated in cases with repeated exposure and/or interrupted treatments [27, 28]. One mechanism that increases this susceptibility the fact that some STIs, such as urethritis, damage epithelial surfaces in the genital tract, thus facilitating other infections, including HIV [29]. Unprotected sex between prisoners can facilitate STIs transmission. These infections, when untreated, can lead to rapid spread within the prison environment and in the external community as well [30]. Our study showed that, when compared to individuals who received intimate visit, those who reported not receiving it had almost nine times more chances of HIV infection. Important for the context of this study, risky sexual relations can occur in exchange for benefits or due to coercion (i.e., sexual violence). Consequently, there is a complex interaction of multiple determinants of risky behaviors among this population.

IDU seems to be the main risk factor associated with HCV infection in prison populations. Fiore and collaborators provided evidence that IDU were significantly less likely of receiving previous treatment for HCV in comparison to inmates without an active infection [6]; indeed, recent studies indicate that IDU have up to eight times more risk of contracting this virus [18, 21, 23], which is very similar to the results reported here. From an epidemiological perspective, these findings–albeit elevated–are not surprising, given that IDU in prisons account for up to 38% of inmates in Europe and 55% in Australia; in these same regions, IDU in the general population is estimated to be around 0.3% [31]. Data from another Brazilian state revealed a prevalence ratio of 5.3% (95% CI 1.97–13.37) of inmates with active HCV infection that were also IDU [24].

Older age and recidivism were risk factors associated with positive anti-HCV serological results in the current study. This could be related to prolonged exposure to biobehavioral variables that underpin STI infection [21]. Notably, these findings are aligned with past reports [32, 33]; however, they could represent some failure by the state in protecting individuals under custody and when they leave the penitentiary system [9]. Indeed, evidence suggests higher syringe sharing, HIV and HCV infection, and increase mortality shortly after inmates are released [34, 35]. Thus, a change in the environment can result in interruptions on a series of protective measures, which once again support the idea of continued assistance to those who enter the penitentiary system [18].

The multivariate model did not maintain the role of homosexual relations and piercing usage–significant in the analyses reported in Table 2 –in relation to positive anti-HCV serological results. In addition, the apparent contradicting result showing that individuals without piercing had a higher seroprevalence of anti-HCV antibodies must be examined carefully. Even if there is scarce data on the prevalence of piercings within prisons, it is undeniable that this practice poses a potential health risk since instruments for skin perforation can be contaminated by infected blood or body fluids, thus increasing the changes of acquiring STIs, such as HCV [36, 37].

Preventive campaigns were related to increased risk for HIV, which again might appear surprising at glance. However, the dynamic of reverse causality could underpin these results. As such, although the inmates have knowledge about STIs, they perhaps do not translate these into protective behaviors. It could also be the case that, for being already infected with HIV, those individuals are perhaps more prone in attending such campaigns for various reasons, such as expanding their social support network or sharing their very own experiences to help others. Indeed, research suggests that more than half of the prison population enter the system without any prior information on STIs and HIV [18, 38].

In summary, the study shows relevant data to public health and contributes with the lack of information concerning STIs in the studied population [19]. The seroprevalence of anti-HCV antibodies (2.7%) is relatively lower when compared to other national and international studies that show estimates ranging from 2.4% to 17% [21, 24, 39, 40]; nonetheless, the presence of anti-HCV antibodies was five times higher in this study than the estimated prevalence (0.53%) for the Brazilian population [41]. In turn, HIV prevalence (1.6%) was lower if compared to the 3.8% estimates for the global prison population [8]; it was likewise below the indices seen among key Brazilian populations, such as sex workers (5%), gays and other men who have sex with men (18%), transgender people, people deprived of liberty and people who use alcohol and other drugs (5%), yet higher when compared to the general population (0.4%) [42].

Failure to detect and promptly treat prisoners’ health, as well as the denial of factors that contribute to the spread of STIs result in higher costs for both detainees and taxpayers [38]. Therefore, it is advisable to conduct further studies targeting the prison population to obtain clearer estimates of STIs in the country [43]. Efforts aiming to better understand the dynamics of transmission, including organizational (testing policies, access to medicines, condom supply), pathophysiological (genotypes, resistance, co-infections, acceptability of medications), and violence aspects among inmates (blood-blood contact, sexual contact) might guide STIs programs in prisons. Moreover, treatment with direct-acting antivirals of HCV-infected inmates is paramount for reducing virus circulation, with possible benefits to the general population [4446].

Finally, readers are adverted that this study has some important limitations, including a relatively low number of individuals with positive serological results, which could interfere in the accurate calculation of OR. Moreover, we performed serologic testing for HCV but were unable to confirm active infections by HCV-RNA, which certainly needs to be accounted in future studies for a more precise estimation of active infections [6]. In addition, findings could not reflect the situation of other types of prisons, including non-closed regimen, juvenile detention centers, and women’s prisons [20, 24]. Future studies might take these limitations into account to expand our knowledge on the burden of STIs in the Brazilian prisons.

Conclusions

Prisons are institutions with intensive concentration of adverse social, economic, and structural factors that facilitate the dissemination of viruses. The fragile infrastructure of Brazilian detention centers, including the lack of proper health care, contribute to prisoners’ higher exposure to illnesses, which characterizes this population as key vectors in propagating HIV and HCV. As healthcare services in prisons are severely affected due to numerous factors, a change in perspective is needed since these environments may be crucial for communities in reducing the circulation of STIs. Thus, policies aiming at testing for HIV, HCV, and other infections upon admission and during incarceration are urgent.

Moreover, efforts in understanding risk factors associated with HIV and HCV are paramount to guide robust public policies, grounded on the knowledge of STIs dynamics and their socioeconomic and cultural specificities. Inside these institutions, harm reduction measures have shown encouraging results, albeit external communities still condemn these practices. Consequently, interventions need to take place inside and outside prisons, ensuring that public health services are available after release and that behaviors that maintain stigma and prejudice are tackled within communities.

Data Availability

Data cannot be shared publicly because of the Resolution NHC number 466 (http://conselho.saude.gov.br/resolucoes/2012/Reso466.pdf), items “II.25”, “III 1 q”, and “IV.3 e” states that researchers might use and share the material and data obtained in the research exclusively according to the consent of the participant and/or institutions and sharing these details must be approved beforehand. Data are available from the Western Paraná State University Institutional Ethics Committee (contact via cep.prppg@unioeste.br) for researchers who meet the criteria for access to confidential data.

Funding Statement

This study has been funded by the Brazilian Ministry of Health [Ministério da Saúde - BR; grant 797322/2013].

References

  • 1.Behzadifar M, Gorji HA, Rezapour A, Bragazzi NL. Prevalence of hepatitis C virus infection among prisoners in Iran: a systematic review and meta-analysis. Harm Reduct J. 2018;15: 24. doi: 10.1186/s12954-018-0231-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Guimarães MDC, Carneiro M, Abreu DMX de, França EB. Mortalidade por HIV/Aids no Brasil, 2000–2015: motivos para preocupação? Rev Bras Epidemiol. 2017;20: 182–190. doi: 10.1590/1980-5497201700050015 [DOI] [PubMed] [Google Scholar]
  • 3.Boletim Epidemiológico de Hepatites Virais—2018. In: Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis [Internet]. [cited 11 Jan 2021]. Available: http://www.aids.gov.br/pt-br/pub/2018/boletim-epidemiologico-de-hepatites-virais-2018
  • 4.Boletim Epidemiológico HIV/Aids 2020. In: Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis [Internet]. [cited 10 Jan 2021]. Available: http://www.aids.gov.br/pt-br/pub/2020/boletim-epidemiologico-hivaids-2020
  • 5.Soares Filho MM, Bueno PMMG, Soares Filho MM, Bueno PMMG. Demography, vulnerabilities and right to health to Brazilian prison population. Ciênc Amp Saúde Coletiva. 2016;21: 1999–2010. doi: 10.1590/1413-81232015217.24102015 [DOI] [PubMed] [Google Scholar]
  • 6.Fiore V, De Matteis G, Ranieri R, Saderi L, Pontali E, Muredda A, et al. HCV testing and treatment initiation in an Italian prison setting: A step-by-step model to micro-eliminate hepatitis C. Int J Drug Policy. 2021;90: 103055. doi: 10.1016/j.drugpo.2020.103055 [DOI] [PubMed] [Google Scholar]
  • 7.Opitz-Welke A, Lehmann M, Seidel P, Konrad N. Medicine in the Penal System. Dtsch Ärztebl Int. 2018;115: 808–814. doi: 10.3238/arztebl.2018.0808 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Dolan K, Wirtz AL, Moazen B, Ndeffo-mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. The Lancet. 2016;388: 1089–1102. doi: 10.1016/S0140-6736(16)30466-4 [DOI] [PubMed] [Google Scholar]
  • 9.Beyrer C, Kamarulzaman A, McKee M. Prisoners, prisons, and HIV: time for reform. The Lancet. 2016;388: 1033–1035. doi: 10.1016/S0140-6736(16)30829-7 [DOI] [PubMed] [Google Scholar]
  • 10.Iguchi MY, London JA, Forge NG, Hickman L, Fain T, Riehman K. Elements of well-being affected by criminalizing the drug user. Public Health Rep. 2002;117: S146–S150. [PMC free article] [PubMed] [Google Scholar]
  • 11.Kutateladze BL, Andiloro NR, Johnson BD, Spohn C. Cumulative disadvantage: Examining racial and ethnic disparity in prosecution and sentencing. Criminology. 2014;52: 514–551. doi: 10.1111/1745-9125.12047 [DOI] [Google Scholar]
  • 12.Bromberg DJ, Mayer KH, Altice FL. Identifying and managing infectious disease syndemics in patients with HIV. Curr Opin HIV AIDS. 2020; Publish Ahead of Print. doi: 10.1097/COH.0000000000000631 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Murphy Y, Sapers H. Prison Health as Public Health in Ontario Corrections. J Community Saf Well-Being. 2020;5: 19. doi: 10.35502/jcswb.122 [DOI] [Google Scholar]
  • 14.McLeod KE, Butler A, Young JT, Southalan L, Borschmann R, Sturup-Toft S, et al. Global Prison Health Care Governance and Health Equity: A Critical Lack of Evidence. Am J Public Health. 2020;110: 303–308. doi: 10.2105/AJPH.2019.305465 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Ojikutu BO, Srinivasan S, Bogart LM, Subramanian SV, Mayer KH. Mass incarceration and the impact of prison release on HIV diagnoses in the US South. PloS One. 2018;13: e0198258. doi: 10.1371/journal.pone.0198258 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Spaulding A, Anderson E, Khan M, Taborda-Vidarte C, Phillips J. HIV and HCV in U.S. Prisons and Jails: The Correctional Facility as a Bellwether Over Time for the Community’s Infections. AIDS Rev. 2017;19. doi: 10.24875/AIDSRev.M17000006 [DOI] [PubMed] [Google Scholar]
  • 17.Dolan K, Moazen B, Noori A, Rahimzadeh S, Farzadfar F, Hariga F. People who inject drugs in prison: HIV prevalence, transmission and prevention. Int J Drug Policy. 2015;26: S12–S15. doi: 10.1016/j.drugpo.2014.10.012 [DOI] [PubMed] [Google Scholar]
  • 18.Wirtz AL, Yeh PT, Flath NL, Beyrer C, Dolan K. HIV and Viral Hepatitis Among Imprisoned Key Populations. Epidemiol Rev. 2018;40: 12–26. doi: 10.1093/epirev/mxy003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Cordeiro EL, Da Silva TM, Silva LSR da, Pereira CE de A, Patricio FDB, Silva CM da. Perfil epidemiológico dos detentos: patologias notificáveis. Av En Enferm. 2018;36: 170–178. doi: 10.15446/av.enferm.v36n2.68705 [DOI] [Google Scholar]
  • 20.Sgarbi RVE, Carbone A da SS, Paião DSG, Lemos EF, Simionatto S, Puga MAM, et al. A Cross-Sectional Survey of HIV Testing and Prevalence in Twelve Brazilian Correctional Facilities. Yu X-F editor. PLOS ONE. 2015;10: e0139487. doi: 10.1371/journal.pone.0139487 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Zampino R, Coppola N, Sagnelli C, Di Caprio G, Sagnelli E. Hepatitis C virus infection and prisoners: Epidemiology, outcome and treatment. World J Hepatol. 2015;7: 2323–2330. doi: 10.4254/wjh.v7.i21.2323 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Alizadeh AHM. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan—Iran. World J Gastroenterol. 2005;11: 4085. doi: 10.3748/wjg.v11.i26.4085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatol Baltim Md. 2013;58: 1215–1224. doi: 10.1002/hep.26387 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Puga MAM, Bandeira LM, Pompilio MA, Croda J, Rezende GR de, Dorisbor LFP, et al. Prevalence and Incidence of HCV Infection among Prisoners in Central Brazil. Khudyakov YE, editor. PLOS ONE. 2017;12: e0169195. doi: 10.1371/journal.pone.0169195 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Adams LM, Kendall S, Smith A, Quigley E, Stuewig JB, Tangney JP. HIV Risk Behaviors of Male and Female Jail Inmates Prior to Incarceration and One Year Post-Release. AIDS Behav. 2013;17: 2685–2694. doi: 10.1007/s10461-011-9990-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Bielen R, Stumo SR, Halford R, Werling K, Reic T, Stöver H, et al. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries. Harm Reduct J. 2018;15: 25. doi: 10.1186/s12954-018-0230-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.McClelland RS, Lavreys L, Katingima C, Overbaugh J, Chohan V, Mandaliya K, et al. Contribution of HIV-1 infection to acquisition of sexually transmitted disease: a 10-year prospective study. J Infect Dis. 2005;191: 333–338. doi: 10.1086/427262 [DOI] [PubMed] [Google Scholar]
  • 28.Pedhambkar R, Pedhambkar B, Kura M. Study of risk factors associated with HIV seropositivity in STD patients at Mumbai, India. Sex Transm Infect. 2001;77: 388–389. doi: 10.1136/sti.77.5.388 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ward H, Rönn M. The contribution of STIs to the sexual transmission of HIV. Curr Opin HIV AIDS. 2010;5: 305–310. doi: 10.1097/COH.0b013e32833a8844 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Johnson RC, Raphael S. The Effects of Male Incarceration Dynamics on Acquired Immune Deficiency Syndrome Infection Rates among African American Women and Men. J Law Econ. 2009;52: 251–293. doi: 10.1086/597102 [DOI] [Google Scholar]
  • 31.European Monitoring Centre for Drugs and Drug Addiction. Prisons and drugs in Europe: the problem and responsesEMCDDA Selected issues. LU: Publications Office; 2012. Available: https://data.europa.eu/doi/10.2810/73390 [Google Scholar]
  • 32.Bartlett SR, Fox P, Cabatingan H, Jaros A, Gorton C, Lewis R, et al. Demonstration of Near-Elimination of Hepatitis C Virus Among a Prison Population: The Lotus Glen Correctional Centre Hepatitis C Treatment Project. Clin Infect Dis. 2018;67: 460–463. doi: 10.1093/cid/ciy210 [DOI] [PubMed] [Google Scholar]
  • 33.Kuncio DE, Newbern EC, Fernandez-Viña MH, Herdman B, Johnson CC, Viner KM. Comparison of Risk-Based Hepatitis C Screening and the True Seroprevalence in an Urban Prison System. J Urban Health. 2015;92: 379–386. doi: 10.1007/s11524-015-9945-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Cepeda JA, Niccolai LM, Lyubimova A, Kershaw T, Levina O, Heimer R. High-risk behaviors after release from incarceration among people who inject drugs in St. Petersburg, Russia. Drug Alcohol Depend. 2015;147: 196–202. doi: 10.1016/j.drugalcdep.2014.11.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Gough E, Kempf MC, Graham L, Manzanero M, Hook EW, Bartolucci A, et al. HIV and hepatitis B and C incidence rates in US correctional populations and high risk groups: a systematic review and meta-analysis. BMC Public Health. 2010;10: 777. doi: 10.1186/1471-2458-10-777 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Moazen B, Saeedi Moghaddam S, Silbernagl MA, Lotfizadeh M, Bosworth RJ, Alammehrjerdi Z, et al. Prevalence of Drug Injection, Sexual Activity, Tattooing, and Piercing Among Prison Inmates. Epidemiol Rev. 2018;40: 58–69. doi: 10.1093/epirev/mxy002 [DOI] [PubMed] [Google Scholar]
  • 37.Yang S, Wang D, Zhang Y, Yu C, Ren J, Xu K, et al. Transmission of Hepatitis B and C Virus Infection Through Body Piercing: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015;94: e1893. doi: 10.1097/MD.0000000000001893 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Ravlija J, Vasilj I, Marijanović I, Vasilj M. Risk behaviour of prison inmates in relation to HIV/STI. Psychiatr Danub. 2014;26 Suppl 2: 395–401. [PubMed] [Google Scholar]
  • 39.Varan AK, Mercer DW, Stein MS, Spaulding AC. Hepatitis C Seroprevalence among Prison Inmates since 2001: Still High but Declining. Public Health Rep. 2014;129: 187–195. doi: 10.1177/003335491412900213 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Gahrton C, Westman G, Lindahl K, Öhrn F, Dalgard O, Lidman C, et al. Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County. BMC Infect Dis. 2019;19: 955. doi: 10.1186/s12879-019-4581-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Benzaken AS, Girade R, Catapan E, Pereira GFM, Almeida EC de, Vivaldini S, et al. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach. Braz J Infect Dis. 2019;23: 182–190. doi: 10.1016/j.bjid.2019.04.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Benzaken AS, Pereira GFM, Costa L, Tanuri A, Santos AF, Soares MA. Antiretroviral treatment, government policy and economy of HIV/AIDS in Brazil: is it time for HIV cure in the country? AIDS Res Ther. 2019;16: 19. doi: 10.1186/s12981-019-0234-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Magri MC, Ibrahim KY, Pinto WP, França FO de S, Bernardo WM, Tengan FM. Prevalence of hepatitis C virus in Brazil’s inmate population: a systematic review. Rev Saúde Pública. 2015;49: 1–10. doi: 10.1590/s0034-8910.2015049005472 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Pontali E, Fiore V, Ialungo AM, Ranieri R, Mollaretti O, Barbarini G, et al. Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy. Int J Drug Policy. 2018;59: 50–53. doi: 10.1016/j.drugpo.2018.06.017 [DOI] [PubMed] [Google Scholar]
  • 45.Bautista-Arredondo S, González A, Servan-Mori E, Beynon F, Juarez-Figueroa L, Conde-Glez CJ, et al. A Cross-Sectional Study of Prisoners in Mexico City Comparing Prevalence of Transmissible Infections and Chronic Diseases with That in the General Population. PLOS ONE. 2015;10: e0131718. doi: 10.1371/journal.pone.0131718 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Jaquet A, Wandeler G, Tine J, Dagnra CA, Attia A, Patassi A, et al. HIV infection, viral hepatitis and liver fibrosis among prison inmates in West Africa. BMC Infect Dis. 2016;16: 249. doi: 10.1186/s12879-016-1601-4 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Yury E Khudyakov

12 May 2021

PONE-D-21-05227

Prevalence and associated factors of HIV and  Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study

PLOS ONE

Dear Dr. Wendt,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Your manuscript was reviewed by 2 experts in the field. Both identified many important problems in your submission and provided copious comments. Please consider the attached comments and provide point-by-point responses.

Please submit your revised manuscript by Jun 10 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Yury E Khudyakov, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

  1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified whether consent was informed.

3. Please provide additional information regarding the considerations  made for the prisoners included in this study. For instance, please discuss whether participants were able to opt out of the study and whether individuals who did not participate receive the same treatment offered to participants.

4. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as:

a) the recruitment date range (month and year),

b) the names of the 11 maximum security prisons,

c) a table of relevant demographic details,

d) a statement as to whether your sample can be considered representative of a larger population, and

e) a description of how participants were recruited.

5. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

5a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

5b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Reviewer comments

Manuscript ID: PONE-D-21-05227

Title" Prevalence and associated factors of HIV and Hepatitis C in Brazilian high-security

3 prisons: A state-wide epidemiological study".

Generally speaking:

Thank you for providing me the opportunity to review this manuscript that raises important critical issues about assessing the Prevalence and associated factors of HIV and Hepatitis C in Brazilian high-security 3 prisons. Such assessment will provide concrete data that will help in the micro-elimination of HCV. Definitely, the awareness about what is going on in prisoners is essential and would be great if the authors could provide in addition the situation of the action taken by the government e.g treatment options, strategy development and what is planned for this particular at risk groups

Following are my specific comments:

Comment:1

1. Title: is specific and reflective of the research work content.

Comment:2

2. Abstract:

a) Background –correct with a sentence focused on a key idea explaining why this topic was chosen.

b) Objectives – add the risk factors under the investigation

c) Methodology - correct

d) Results - need some quantification on the risk factors ….

e) Conclusions- are too general; the conclusion should mention specific challenges to be met as well as specific recommendations that is related to the findings of the manuscript.

Comment:3

3. Introduction:

Well written explaining why this topic was chosen for analysis in this article.

Comment:4

Methods:

Generally, the information mentioned under the methodology deficient and should be divided into several sub-sections as follow:

a. Type of the study

b. Study setting

c. Study Participants:

d. Sample type and size: The basis of sample size calculation should be mentioned to know the confidence level and the margin of error.

e. Measurements- OR is calculated for both the comparative cross section study and case control study as well. Please refer to the comment 5-2 in the study section.

Comment:5 Results: has to be badly improved for all the tables

5. 1 Results – should be separated from the discussion section

5.2 The mentioned sample size was 1,154 with overall prevalence of HCV and HIV detected among 1,132 meaning that only 22 cases were –ve. Accordingly, the authors has to mention how they calculated the Odds Ratio with this very small number of the comparative group. This imply that All the tables should include two columns for number and % of HCV +ve and HCV _ve and 2 columns for HIV +ve and –ve for the results to be more understandable.

5.2 line 140 and 141 indicated that the prevalence of HCV (2.7%) and HIV (1.6%) while the tables mentioned an overall prevalence 1,132: please clarify

Comment:6

6. Discussion: should be separate section, focusing discussion on critical or essential findings and explicitly linking the conclusions with the reported data should be more emphasized.

Comment:7

7. Conclusion – is general one, it should be specific and explicitly linking the conclusions with the reported data, write suggestions for improvement as well as add limitations of the proposed technique to the conclusion section and provide recommendations for future research that is focused on the findings

8. References: adequate

Reviewer #2: Having reliable data on the HIV and HCV infection spread within closed prison communities is certainly very important, especially in this era of highly active antivirals against the two viruses. To achieve the goal of reducing reservoirs of infection in humans and the infections spread, until eradication for HCV, it is necessary to identify all difficult-to-reach and unaware patients in the few places where this is possible. Prisons are certainly one of these. For this reason I think this paper have a great interest. Unfortunately, the manuscript present many critical and incomprehensible points, starting with how the sample was collected. The authors speak of a randomization of 8,142 inmates of 11 correctional institutions, but do not explain in any way how they arrived at 1,132 HCV screening tests and, above all, how many inmates were tested for each prison (only a generic "prevalence by municipality" is indicated). Furthermore, those who tested positive seems to referred as infected without an HCV-RNA determination and without having been defined the proportion of viraemic HCVs to be treated with DAA.

For these reasons, we think the paper can be improved and become sufficient for publication on PLOS ONE with the following corrective actions:

- To improve the comprehensibility and clarity of the study, our advice is to separate the chapter of materials and methods into paragraphs as follows: study conduction, sample size and statistical analysis, ethical issues. Please provide sample size determination including it in the described paragraph or mention it as limitation of the study.

- Similarly, it is advisable to separate the results and discussion section into two paragraphs. The results should be described more systematically and subsequently with no judgements on the results. In a separate chapter the discussion should compare the results with international literature in total and stratified in the different cohorts, with special regard on IDU patients cohort. Here a list of examples in literature that may help:

DOI 10.1007/s10654-014-9958-4

- HCV serologic positivity found in enrolled patients if not followed by determination of a positive HCV-RNA cannot be considered as active infection. It is never mentioned if viral load in patients with positive antibodies for HCV was performed. Throughout the text of the article the term HCV infection is therefore used improperly and it should be replaced. We believe for ethical concerns HCV-RNA determination should be at least scheduled in positive HCV antibodies patients to help diagnosis and start treatment. Nevertheless this data could be included in the study and compared. Here a list of other examples in literature:

https://doi.org/10.1111/liv.14745

https://doi.org/10.1016/j.drugpo.2018.06.017

https://doi.org/10.1016/j.drugpo.2020.103055

- There is no mention of the study limitations.

- The conclusions of the study that call for urgent change in perspective are not supported by the evidence of the study itself that shows relatively low HCV seroprevalence.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Babudieri Sergio

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: My Reviewer comments for Plos One docx.docx

PLoS One. 2021 Jul 26;16(7):e0255173. doi: 10.1371/journal.pone.0255173.r002

Author response to Decision Letter 0


31 May 2021

To the editorial board:

Many thanks for considering this manuscript for publication. On behalf of all the collaborators, please accept our gratitude in receiving such a constructive feedback on our paper. We broaden this sentiment to the reviewers, who gave us not only their precious time but also their insightful analysis.

Responses to every comment and suggestions are detailed below. Changes to the revised manuscript are now highlighted in red color.

Please, do not hesitate to get in contact if there are any other issues involving our article that can be clarified.

Yours sincerely,

Guilherme Welter Wendt, PhD

----------------------------------

EDITORIAL

Comment e.1: Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response e.1: The manuscript has been reviewed and updated to adhere more closely to PLOS ONE’s style requirements. We carefully investigated the template, and all the formatting seems to be correct now – including file naming.

Comment e.2: Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified whether consent was informed.

Response e.2: We have provided further details on the processes of informed consent employed by this study. These processes were reviewed and approved by the Human Research Ethics Committee of the Western Paraná State University and adhered with Brazil’s National Statement on Ethical Conduct in Human Research and are highlighted in the revised manuscript (p. 6, under the procedures section).

Comment e.3: Please provide additional information regarding the considerations made for the prisoners included in this study. For instance, please discuss whether participants were able to opt out of the study and whether individuals who did not participate receive the same treatment offered to participants.

Response e.3: We thank the editor for pointing this out and we have clarified this info. The revised version now contains these descriptions (p. 6, section “Procedures”).

Comment e.4: In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as:

a) the recruitment date range (month and year),

b) the names of the 11 maximum security prisons,

c) a table of relevant demographic details,

d) a statement as to whether your sample can be considered representative of a larger population, and

e) a description of how participants were recruited.

Response e.4: All these points were addressed and appear in the revised version of our manuscript. Hence, information on a) is given on the page 5, section Study design and setting; b) appears on the page 5, section Study design and setting; c) now appears in a new table (Table 1); d) is on page 5, also flagged in red color; and e) is on pages 5-6, within the procedures section.

Comment e.5: We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

5a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

5b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

Response e.5: In our revised cover letter, we addressed the prompts 5a and 5b. In short, research with human beings is extremely strict in Brazil and sometimes international scholars “get annoyed” with our local guidelines. We would like that the process was simpler, but unfortunately, we must adhere with the law.

The issue of sharing our de-identified data set involves the nature of the sample (defined as vulnerable by the National Health Council - NHC) and the conditions imposed by the institutions/prisons and our State Penitentiary Department (DEPEN-PR), that did not give prior consent for sharing data with others. According to the NHC resolutions (that must be followed by every Research Ethics Committee, including the one which approved our study) there are some impediments after the year of 2012 when sharing certain type of data, thus resulting in ethical and legal impediments.

As such, the Resolution NHC number 466 (http://conselho.saude.gov.br/resolucoes/2012/Reso466.pdf), items “II.25”, “III 1 q”, and “IV.3 e” states that researchers might use and share the material and data obtained in the research exclusively according to the consent of the participant and/or institutions and sharing these details must be approved beforehand. At the time of data collection, we did not ask for participants and institutional approval for sharing data, including the main institution (DEPEN) and its 11 high security prisons. This was entirely our fault as we did not anticipate this request.

Moreover, NHC has special policies around vulnerability to protect people or groups that, for whatever reasons, have their capacity for self-determination reduced or hindered, or in any way are prevented from opposing resistance, especially with regards to informed consent. For these reasons, most Research Ethics Committee only approve research with this type of sample if scholars assure and limit access to data to a few individuals.

Consequently, we provided now extra information on how to proceed in case of requesting our data. In summary, a justification must be addressed to every prison unit, and then to the State Penitentiary Department, which would examine the request and provide or deny the sharing to third parties; after that, we would have to amend our ethical application with the NHC and with the Western Paraná State University. This process usually does not take long and those interested in accessing the data would receive all our support. We hope this clarification is helpful. We provided the contact details as requested too in the cover letter.

-----------------------------

REVIEWER 1

Comment 1.1:

Abstract:

a) Background – correct with a sentence focused on a key idea explaining why this topic was chosen.

b) Objectives – add the risk factors under the investigation

c) Methodology - correct

d) Results - need some quantification on the risk factors ….

e) Conclusions- are too general; the conclusion should mention specific challenges to be met as well as specific recommendations that is related to the findings of the manuscript.

Response 1.1: We thank the reviewer for these comments on the abstract. We have incorporated all the suggestions that are now clearly highlighted in red color. Thus, we added the key idea of why the topic was chosen (scarcity of studies on HCV and HIV among prisoners, mainly in developing countries, p. 2, lines 30-32), the risk factors investigated (p. 2, line 33) and their quantification (p 2., lines 39-44). We also tried to be specific in the conclusion (pp. 2-3, lines 45-51). In summary, the abstract looks much more complete, informative, and convincing after incorporating these suggestions. Any other comments would be very welcomed.

Comment 1.2: Methods:

Generally, the information mentioned under the methodology deficient and should be divided into several sub-sections as follow:

a. Type of the study

b. Study setting

c. Study Participants:

d. Sample type and size: The basis of sample size calculation should be mentioned to know the confidence level and the margin of error.

e. Measurements- OR is calculated for both the comparative cross section study and case control study as well. Please refer to the comment 5-2 in the study section.

Response 1.2: Our thanks go to the reviewer for these suggestions. In the revised manuscript, we have included all the suggested subheadings (pp. 5-7) and expanded on the sample size calculation (p. 6, lines 125-127), allowing readers to know the confidence level and the margin of error.

Comment 1.3: Results: have to be badly improved for all the tables. Should be separated from the discussion section.

Response 1.3: Following the reviewers’ suggestion, we also separated the result section from the discussion. The revised version of the manuscript now includes some important improvements, including a table with demographic data and the extra details requested (i.e., number of + tests, pp. 10-11). We think that is redundant to provide the number of negative tests since it would pollute the table and is basically the total number of people tested (1,132) minus the positive cases indicated in the columns added). All these changes are clearly highlighted in the file with red font. If is in the opinion of the reviewer that further adjustments are necessary, please, do let us know.

Comment 1.4: 5.2 The mentioned sample size was 1,154 with overall prevalence of HCV and HIV detected among 1,132 meaning that only 22 cases were negative. Accordingly, the authors have to mention how they calculated the Odds Ratio with this very small number of the comparative group. This imply that All the tables should include two columns for number and % of HCV +ve and HCV negative and 2 columns for HIV + and HIV – for the results to be more understandable.

5.2 line 140 and 141 indicated that the prevalence of HCV (2.7%) and HIV (1.6%) while the tables mentioned an overall prevalence 1,132: please clarify

Response 1.4: Apologies for this typo in the methods section; the correct sample size is the one informed in the study’s abstract (1,132). We corrected Table 1 (that now reads as Table 2 after adding a table with demographics [new Table 1]) and the information on the prevalence spotted by the reviewer now matches the sample size (p. 6, line 122). Columns were added with positive results. Once again, if needed, we can add the negative tests, albeit we do believe that it is redundant since it is a matter of subtracting the + values out of the 1,132 participants. Regarding the calculation of the odds ratio, the reviewer is right that odds can be inflated/biased with different group sizes. However, we consulted with a biostatistician and we tried to address these issues by using multivariate procedures followed by 95% CI following past research on the matter already published at Plos One (i.e., https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0139487 and https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0169195). In our study’s limitations, we added this as a factor to be considered as well (p. 18, lines 340-342). Suggestions to improve these issues would be again very welcomed.

Comment 1.5: Discussion: should be separate section, focusing discussion on critical or essential findings and explicitly linking the conclusions with the reported data should be more emphasized.

Response 1.5: This revised manuscript now includes several improvements in the discussion, with addition of substantial new literature. Following the recommendations of both reviewers, we discussed a little further the role of IDU in terms of national and international literature (pp. 14-18) while also linking our conclusions with the reported data. The reviewer might notice that we could have made better word choices now, with shorter sentences and more explicit links with the data collected.

Comment 1.6: Conclusion – is general one, it should be specific and explicitly linking the conclusions with the reported data, write suggestions for improvement as well as add limitations of the proposed technique to the conclusion section and provide recommendations for future research that is focused on the findings.

Response 1.6: The reviewer offers a useful suggestion, which we adopted entirely. Consequently, the revised file contains a new conclusion (p. 19, lines 352-361) that is more focused on our data, that suggests improvements for future studies, while our limitations were presented in the previous section (p. 18, lines 340-348).

----------------------------

REVIEWER 2

Comment 2.1: The authors speak of a randomization of 8,142 inmates of 11 correctional institutions, but do not explain in any way how they arrived at 1,132 HCV screening tests and, above all, how many inmates were tested for each prison (only a generic "prevalence by municipality" is indicated). Furthermore, those who tested positive seems to referred as infected without an HCV-RNA determination and without having been defined the proportion of viraemic HCVs to be treated with DAA. For these reasons, we think the paper can be improved and become sufficient for publication on PLOS ONE.

Response 2.1: We thank the reviewer for these three initial suggestions. Regarding how we arrived at the final sample of 1,132, the revised manuscript now adds this information (p. 6, lines 122-127). Unfortunately, we did not have funds to test the entirely population, so we had to use a randomized sample. The number of inmates tested for each prison is presented on page 8, Table 1. Finally, we rephased the word “infected” for having “anti-HCV antibodies”. We read the reviewers publications on the topic and admire his expertise. So, further suggestions to improve these issues would be very welcomed.

Comment 2.2: To improve the comprehensibility and clarity of the study, our advice is to separate the chapter of materials and methods into paragraphs as follows: study conduction, sample size and statistical analysis, ethical issues. Please provide sample size determination including it in the described paragraph or mention it as limitation of the study.

Response 2.2: We followed all these suggestions. The reviewer will find the separation of the methods section into paragraphs (pp. 5-7) and sample size determination (p. 6, lines 125-127). If there are any other improvements that the reviewer sees as necessary, we would be glad to work on them.

Comment 2.3: It is advisable to separate the results and discussion section into two paragraphs. The results should be described more systematically and subsequently with no judgements on the results. In a separate chapter the discussion should compare the results with international literature in total and stratified in the different cohorts, with special regard on IDU patients cohort. Here a list of examples in literature that may help: DOI 10.1007/s10654-014-9958-4

Response 2.3: The reviewer rightly notes that results and discussion must form different sections. We performed those changes. As for the comparisons with international literature, we expanded the discussions in terms of the general prison population (p. 15, lines 252-261) and also in terms of inject drug users, including data from Brazil (Mato Grosso State) (p. 14, lines 247-251). We thank the reviewer for suggesting the literature, which has been incorporated in our revised file. Apart from these comments, there are new paragraphs in the discussion clearly marked with red font.

Comment 2.4: HCV serologic positivity found in enrolled patients if not followed by determination of a positive HCV-RNA cannot be considered as active infection. It is never mentioned if viral load in patients with positive antibodies for HCV was performed. Throughout the text of the article the term HCV infection is therefore used improperly and it should be replaced. We believe for ethical concerns HCV-RNA determination should be at least scheduled in positive HCV antibodies patients to help diagnosis and start treatment. Nevertheless, this data could be included in the study and compared. Here a list of other examples in literature:

https://doi.org/10.1111/liv.14745

https://doi.org/10.1016/j.drugpo.2018.06.017

https://doi.org/10.1016/j.drugpo.2020.103055.

Response 2.4: Indeed, the study presents seroprevalence and each test was registered in individuals’ medical records when consent was obtained. We apologize for not making that clear beforehand. As such, in our procedures section (p. 6), we included that “Those who agreed to share the results from the serological testing with the institutions medical personnel had their records updated and, if necessary, guidance was offered to health staff.” We also corrected the usage of “infection” or “HCV infected” in the text as already mentioned.

The literature recommended by the reviewer has been extremely useful in strengthening our paper. Consequently, we not only included these papers to support even more some claims made in the introduction, but we also expanded our discussion in line with previous recommendations given by the same reviewer (“the discussion should compare the results with international literature”). Once again, these are marked in red font.

Comment 2.5: There is no mention of the study limitations.

- The conclusions of the study that call for urgent change in perspective are not supported by the evidence of the study itself that shows relatively low HCV seroprevalence.

Response 2.5: We are thankful for these comments. We included several limitations of our study (p. 18, lines 340-349). In respect to our call for “urgent change”, the rationale we used took also into account the role played by prisoners in propagating HIV and HCV. We amended our conclusions to tone down those claims (p. 19). If there are any other suggestions, we would be glad to tackle.

Attachment

Submitted filename: Response to reviewers.docx

Decision Letter 1

Yury E Khudyakov

12 Jul 2021

Seroprevalence and associated factors of HIV and  Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study

PONE-D-21-05227R1

Dear Dr. Wendt,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Yury E Khudyakov, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: All comments have been addressed clearly in the corrected version. The text is now well structured with a clear separation of the paragraphs. The sample size is described and the statistics are reported. We hope this study continues with the determination of active infections in order to be able to estimate the active ones and that the infected patients may reach treatment.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Prof. Ammal Mokhtar Metwally

Reviewer #2: No

Acceptance letter

Yury E Khudyakov

16 Jul 2021

PONE-D-21-05227R1

Seroprevalence and associated factors of HIV and  Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study

Dear Dr. Welter Wendt:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Yury E Khudyakov

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: My Reviewer comments for Plos One docx.docx

    Attachment

    Submitted filename: Response to reviewers.docx

    Data Availability Statement

    Data cannot be shared publicly because of the Resolution NHC number 466 (http://conselho.saude.gov.br/resolucoes/2012/Reso466.pdf), items “II.25”, “III 1 q”, and “IV.3 e” states that researchers might use and share the material and data obtained in the research exclusively according to the consent of the participant and/or institutions and sharing these details must be approved beforehand. Data are available from the Western Paraná State University Institutional Ethics Committee (contact via cep.prppg@unioeste.br) for researchers who meet the criteria for access to confidential data.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES